Evaluation of the state of pharmaceutical supply of patients with dementia with Alzheimer disease in Ukraine in accordance with international recommendations





dementia, clinical and economic analysis, drug consumption, pharmaceutical provision of neuropsychiatric patients, Alzheimer's disease


The aim: to assess the state of pharmaceutical provision of patients with dementia in Alzheimer's disease in Ukraine in accordance with international recommendations.

Materials and methods. In our studies, we used data from international guidelines, clinical protocols that regulate the organization of medical and pharmaceutical care for these patients in the USA, Australia, Japan, Germany, Great Britain, Finland, India, Kazakhstan, and Ukraine. The actual state of pharmaceutical provision of these patients in Ukraine was studied using a depersonalized database of medical prescriptions, which operates based on a number of specialized healthcare institutions. In addition, data from the Morion information search system were used. We used general theoretical (historical, formal, graphic, hypothetical-deductive, etc.) and applied (clinical-economic, organizational-economic, mathematical-statistical, etc.) research methods.

Results. It has been established that a consolidated opinion has been formed in the world scientific community regarding the possibility of effective use in the pathogenetic treatment of patients with dementia in Alzheimer's disease of drugs from the groups N06DA Acetylcholinesterase inhibitors and N06DX-Other drugs for use in case of dementia. Thus, the pharmaceutical component of international recommendations, clinical protocols for the treatment of patients with dementia in Alzheimer's disease contains four drugs used in pathogenetic therapy. These are N06DA02 Donepezil, N06DA03 Rivastigmine, N06DA04 Galantamine and N06DX01 Memantine. It has been reported that all the above drugs are included in the domestic clinical protocol for the treatment of patients with dementia in Alzheimer's disease, the State Drug Formulary (with the exception of N06DA03 Rivastigmine), and the State Drug Registry. At the same time, all of them were absent from the National List of Essential Drugs, which has an important socio-economic and medical-pharmaceutical significance in the health care system. It was found that patients (200 people) received 2487 prescriptions (100.0 %), among which 9.41 % (234 prescriptions) were drugs used in pathogenetic treatment. There is a highly disproportionate nature of the distribution of prescriptions and consumption by international generic names of drugs. Thus, drugs N06DX01 Memantine accounted for 80.41 % (188 prescriptions) of all prescriptions in the group N06D Drugs for use in dementia, and the consumption rate was UAH 84420.20, which accounted for 91.48 % of the amount of expenses directed to patients with carrying out pathogenetic treatment. Significant dominance of drugs N06DX01 Memantine in the structure of prescriptions and consumption indicates the presence of severe, advanced forms of dementia in patients. This fact once again emphasizes the need for early detection and treatment of cognitive impairment, primarily for the rational use of limited health care resources. We have found that there are no prescriptions for N06D A04 Galantamine preparations, which are recommended by the relevant international recommendations in different countries of the world, as well as by the domestic clinical protocol for the pathogenetic treatment of mild and moderate forms of Alzheimer's disease. At the same time, N06DA05 Ipidacrine preparations were used in the treatment of domestic patients, which are not presented in the pharmaceutical component of international recommendations and protocols governing the pathogenetic treatment of the above-mentioned groups of neuropsychiatric patients.

Conclusions. The peculiarities of the formation of the pharmaceutical component in the organization of the treatment process of patients with dementia in Alzheimer's disease in Ukraine, established by us, allow further research on the development of rational ways of resource provision of neuropsychiatric patients

Author Biographies

Maryna Fedotova, Bukovinian State Medical University


Department of Pharmacy

Hanna Panfilova, National University of Pharmacy

Doctor of Pharmaceutical Sciences, Professor

Department of Organization and Economics of Pharmacy

Liliia Hala, Bogomolets National Medical University

Doctor of Pharmaceutical Sciences, Associate Professor

Department of Organization and Economics of Pharmacy

Alla Lebedyn, National University of Pharmacy

PhD, Assistant

Department of Organization and Economics of Pharmacy

Liusine Simonian, National University of Pharmacy

PhD, Assistant

Department of Organization and Economics of Pharmacy

Oleg Gerush, Bukovinian State Medical University

PhD, Аssociate Professor, Head of Department

Department of Pharmacy

Gennadii Iurchenko, National University of Pharmacy

PhD, Аssociate Professor

Department of Organization and Economics of Pharmacy

Аlina Palamar, Bukovinian State Medical University

PhD, Senior Lecturer

Department of Pharmacy

Nataliia Sholoiko, Bogomolets National Medical University

PhD, Associate Professor

Department of Organization and Economics of Pharmacy

Mariia Velia, Bukovinian State Medical University


Department of Pharmacy


  1. Cummings, J., Aisen, P. S., DuBois, B., Frölich, L,. Jack, Jr. C. R., Jones, R. W. et. al. (2016). Drug development in Alzheimer's disease: the path to 2025. Alzheimer's Research & Therapy, 8 (1). doi: http://doi.org/10.1186/s13195-016-0207-9
  2. Fitzpatrick-Lewis, D., Warren, R., Ali, M. U., Sherifali, D., Raina, P. Treatment for mild cognitive impairment: a systematic review and meta-analysis. CMAJ Open, 3 (4), 419–427. doi: http://doi.org/10.9778/cmajo.20150057
  3. Scheltens, N., Galindo-Garre, F., Pijnenburg, Y., van der Vlies, A. E., Smits L. L., Koene, T. et. al. (2016). The identtification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. Journal of Neurology, Neurosurgery & Psychiatry, 87, 235–243. doi: http://doi.org/10.1136/jnnp-2014-309582
  4. Scheltens, N. M. E., Tijms, B. M., Koene, T., Barkhof, F., Teunissen, C. E., Wolfsgruber, S. et. al. (2017). Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. Alzheimer's & Dementia, 13 (11), 1226–1236. doi: http://doi.org/10.1016/j.jalz.2017.03.002
  5. Barreto, P. S., Demougeot, L., Vellas, B., Rolland, Y. (2017). Exercise training for preventing dementia, mild cognitive impairment, and clinically meaningful cognitive decline: a systematic review and meta-analysis. Journals of Gerontology Series A: Biological Sciences & Medical Sciences, 73 (11), 1504–1511. doi: http://doi.org/10.1093/gerona/glx234
  6. Fiest, K. M., Roberts, J. I., Maxwell, C. J., Hogan, D. B., Smith, E. E., Frolkis, A. et. al. (2016). The Prevalence and Incidence of Dementia Due to Alzheimer’s Disease: a Systematic Review and Meta-Analysis. Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques, 43 (S1), S51–S82. doi: http://doi.org/10.1017/cjn.2016.36
  7. Rosa, A. D. L., Olaso-Gonzalez, G., Arc-Chagnaud, C., Millan, F., Salvador-Pascual, A., García-Lucerga, C. et. al. (2020). Physical exercise in the prevention and treatment of Alzheimer's disease. Journal of Sport and Health Science, 9 (5), 394–404. doi: http://doi.org/10.1016/j.jshs.2020.01.004
  8. Global health and aging (2017). World Health Organization. Available at: https://www.nia.nih.gov/sites/default/files/2017-06/global_health_aging.pdf
  9. Dos Santos Picanco, L. C., Ozela, P. F., de Fatima de Brito Brito, M., Pinheiro, A. A., Padilha, E. C., Braga F. S. et. al. (2022). Alzheimer's disease: a review from the pathophysiology to diagnosis, new perspectives for pharmacological treatment. Current Medicinal Chemistry, 25, 3141–3159. doi: http://doi.org/10.2174/0929867323666161213101126
  10. Alzheimer's disease facts and figures: includes a special report on the financial and personal benefits of early diagnosis (2018). Alzheimer's Association. Available at: https://www.alz.org/media/homeoffice/facts %20and %20figures/facts-and-figures.pdf
  11. Hebert, L. E., Weuve, J., Scherr, P. A., Evans, D. A. (2013). Alzheimer disease in the United States (2010−2050) estimated using the 2010 census. Neurology, 80, 1778–1783. doi: http://doi.org/10.1212/wnl.0b013e31828726f5
  12. Northey, J. M., Cherbuin, N., Pumpa, K. L., Smee, D. J., Rattray, B. (2018). Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis. British Journal of Sports Medicine, 52, 154–160. doi: http://doi.org/10.1136/bjsports-2016-096587
  13. Orgeta, V., Mukadam, N., Sommerlad, A., Livingston, G. (2019). The Lancet Commission on dementia prevention, intervention, and care: a call for action. Irish Journal of Psychological Medicine, 36, 85–88. doi: http://doi.org/10.1017/ipm.2018.4
  14. Toots, A., Littbrand, H., Boström, G., Hörnsten, C., Holmberg, H., Lundin-Olsson, L. et. al. (2017). Effects of Exercise on Cognitive Function in Older People with Dementia: A Randomized Controlled Trial. Journal of Alzheimer’s Disease, 60 (1), 323–332. doi: http://doi.org/10.3233/jad-170014
  15. Blumenthal, J. A., Smith, P. J., Mabe, S., Hinderliter, A., Lin, P.-H., Liao, L. et. al. (2018). Lifestyle and neurocognition in older adults with cognitive impairments. Neurology, 92 (3), e212–e223. doi: http://doi.org/10.1212/wnl.0000000000006784
  16. Fish, P. V., Steadman, D., Bayle, E. D., Whiting, P. (2019). New approaches for the treatment of Alzheimer’s disease. Bioorganic & Medicinal Chemistry Letters, 29 (2), 125–133. doi: http://doi.org/10.1016/j.bmcl.2018.11.034
  17. Veitc, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C. et. al. (2019). Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia, 15 (1), 106–152. doi:
  18. Devi, G., Scheltens, P. (2018). Heterogeneity of Alzheimer’s disease: consequence for drug trials? Alzheimer’s Research & Therapy, 10 (1). doi: http://doi.org/10.1186/s13195-018-0455-y
  19. Aisen, P. S., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., Frölich, L. et. al. (2017). On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimer’s Research & Therapy, 9 (1). doi: http://doi.org/10.1186/s13195-017-0283-5
  20. Tatulian, S. A. (2022). Challenges and hopes for Alzheimer’s disease. Drug Discovery Today, 27 (4), 1027–1043. doi: http://doi.org/10.1016/j.drudis.2022.01.016
  21. Obsiah rynku preparativ dlia likuvannia khvoroby Altsheimera siahne 12,9 mlrd dol. SShA u 2028 r. (2020) Apteka, 5, 42. Available at: https://www.apteka.ua/article/552579
  22. Sadiq, M. U., Kwak, K., Dayan, E. (2022). Model-based stratification of progression along the Alzheimer disease continuum highlights the centrality of biomarker synergies. Alzheimer’s Research & Therapy, 14 (1). doi: http://doi.org/10.1186/s13195-021-00941-1
  23. Musiek, E. S., Morris, J. C. (2021). Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease. JAMA Neurology, 78 (2), 141–142. doi: http://doi.org/10.1001/jamaneurol.2020.4478
  24. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi), tretynnoi (vysokospetsializovanoi) ta paliatyvnoi medychnoi dopomohy. Dementsiia (2016). Nakaz MOZ Ukrainy No. 736 19.07.2016. Available at: https://www.dec.gov.ua/wp-content/uploads/2019/11/2016_736_ykpmd_dem.pdf
  25. Natsionalnyi perelik osnovnykh likarskykh zasobiv (2009). Postanova Kabinetu Ministriv Ukrainy No. 333. 25.03.2009. Available at: https://moz.gov.ua/uploads/0/3799-nacperelic_dodatok_web.pdf
  26. Pro zatverdzhennia chotyrnadtsiatoho vypusku Derzhavnoho formuliara likarskykh zasobiv ta zabezpechennia yoho dostupnosti (2022). Nakaz MOZ Ukrainy No. 1011. 13.06.2022. Available at: https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-13062022--1011-pro-zatverdzhennja-chotirnadcjatogo-vipusku-derzhavnogo-formuljara-likarskih-zasobiv-ta-zabezpechennja-jogo-dostupnosti
  27. Hudzenko, O. P., Tolochko, V. M. (2003). Farmakoekonomichni standarty likarskoho zabezpechennia pilhovoi katehorii naselennia promyslovykh rehioniv – khvorym tsukrovym i netsukrovym diabetom. Kharkiv: Vyd–vo NFaU, 24.
  28. Fang, J.-Q. (Ed.) (2017). Handbook of Medical Statistics. China: Sun Yat-Sen University.
  29. Kotvitska, A., Volkova, A., Korzh, I., Surikova, I. (2021). Comparative analysis of indicators that determine the effectiveness of the implementation of socio-economic determinants of health in Europe and Ukraine. ScienceRise: Pharmaceutical Science, 3 (31), 34–41. doi: http://doi.org/10.15587/2519-4852.2021.235787




How to Cite

Fedotova, M., Panfilova, H., Hala, L., Lebedyn, A., Simonian, L., Gerush, O., Iurchenko, G., Palamar А., Sholoiko, N., & Velia, M. (2022). Evaluation of the state of pharmaceutical supply of patients with dementia with Alzheimer disease in Ukraine in accordance with international recommendations. ScienceRise: Pharmaceutical Science, (4 (38), 53–61. https://doi.org/10.15587/2519-4852.2022.263415



Pharmaceutical Science